WO2017160156A1 - Synthetic capasaicin analogs as trpv1 agonists - Google Patents
Synthetic capasaicin analogs as trpv1 agonists Download PDFInfo
- Publication number
- WO2017160156A1 WO2017160156A1 PCT/NO2017/050062 NO2017050062W WO2017160156A1 WO 2017160156 A1 WO2017160156 A1 WO 2017160156A1 NO 2017050062 W NO2017050062 W NO 2017050062W WO 2017160156 A1 WO2017160156 A1 WO 2017160156A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutical composition
- phenylcapsaicin
- capsaicin
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
Definitions
- the transient receptor potential cation channel subfamily V member 1 (TrpVl), also known as the capsaicin receptor and the vanilloid receptor 1, is a protein that, in humans, is encoded by the TRPVl gene. It was the first isolated member of the transient receptor potential vanilloid receptor proteins that in turn are a sub-family of the transient receptor potential protein group. This protein is a member of the TRPV group of transient receptor potential family of ion channels.
- TRPVl The function of TRPVl is detection and regulation of body temperature. In addition, TRPVl provides a sensation of scalding heat and pain (nociception).
- TRPVl is a nonselective cation channel that may be activated by a wide variety of exogenous and endogenous physical and chemical stimuli.
- the best-known activators of TRPVl are: temperature greater than 43 °C (109 °F); acidic conditions; capsaicin, the irritating compound in hot chili peppers; and allyl isothiocyanate, the pungent compound in mustard and wasabi.
- the activation of TRPVl leads to a painful, burning sensation.
- Its endogenous activators include: low pH (acidic conditions), the endocannabinoid anandamide, N-oleyl-dopamine, and N-arachidonoyl-dopamine.
- TRPVl receptors are found mainly in the nociceptive neurons of the peripheral nervous system, but they have also been described in many other tissues, including the central nervous system. TRPVl is involved in the transmission and modulation of pain (nociception), as well as the integration of diverse painful stimuli.
- TRPVl agonists The problem with many TRPVl agonists is their toxicity, and side effects. Different antagonist also have different selectivity and therapeutic effects.
- Naturally occurring and isolated capsaicin have been shown to be a potent TRPVl agonist. However the substance is toxic. The available amounts of naturally occurring capsaicin is limited and expensive. Natural capsaicin extracts contains at least 3 isomers, which all have different chemical properties. The amounts of these isomers and type and amount of additional isolated compounds will also depend on the natural source and the isolation procedure. It is thus difficult to obtain capsaicin extracts with sufficiently uniform purity and composition for an intended use. Naturally occuring capsacin has proved difficult to synthezise in high quality and yields. aXichem is a global supplier of natural-analogue industrial compounds and their mission is to develop, patent and market natural- analogue substances.
- aXichem has been focusing on synthetic analogues of natural capsaicin. Phenylcapsaicin is not environmentally harmful and is thus a viable alternative to natural capsaicin within a wide range of uses. aXichem holds European (EP1670310) and US patents (US7446226) on synthetic capsaicin analogs, their synthesis and use as antifouling agent (WO2005025314). These synthetic low toxicity analogs of capsaicin can by synthezised with high purity with a reasonable cost and in high yield. Phenylcapsaicin has proved to be less toxic and far less irritating than natural capsaicin.
- the invention relates to at least one chemical compound with the general formula (1)
- R is a substituent selected from the group of Ci-Cis alkyl, trifluoromethyl, C3-C12 cycloalkyl, phenyl, phenoxy, phenylthio, halogen; or tautomers or salts thereof, for use as TRPV1 agonist(s).
- the inventions also relates to pharmaceutical compositions, formulations and compositions comprising compounds of formula (1) according to claim 1.
- the invention also relates to compounds, formulations and pharmaceutical compositions for treatment of diseases as defined in the claims 7 and 8.
- the invention relates to at least one chemical compound with the general formula (1)
- R is a substituent selected from the group of Ci-Cis alkyl, trifluoromethyl, C3-C12 cycloalkyl, phenyl, phenoxy, phenylthio, halogen; or tautomers or salts thereof, for use as TRPVl agonist(s).
- a preferred compound according to claim 1 is phenylcapsaicin.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound according to any of the claims 1 or 2 and optional carriers and adjuvants, for use as TRPVl agonist(s).
- the invention relates to a combination comprising a compound according to any of the claims 1 or 2 or a composition according to claim 3 with one or more additional antagonist(s) selected form the group consisting of resiniferatoxin, piperine, curcumin, capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide.
- additional antagonist(s) selected form the group consisting of resiniferatoxin, piperine, curcumin, capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide.
- the invention also relates to a pharmaceutical composition according to claim 3 or a combination according to claim 4, wherein the concentration of a compound of formula (1) according to claim 1 is between 2 and 500 ppm, preferably between 2 and 50 ppm even more preferably between 2 and 20 ppm.
- the invention also relates to a compound according to claim 1, a pharmaceutical composition according to claim 3 or a combination according to claim 5, for use as TRPVl agonists in animals, preferably humans.
- a compound according to claim 1 a pharmaceutical composition according to claim 3 or a combination according to claim 4 for treatment or prophylactic use for pain, coughing, asthma, cancer, anxiety, cardiac hypertrophy, diabetes, obesity, metabolic disorders, irritable bowel syndrome (IBS), Ulcus colitis, Crohn's disease.
- IBS irritable bowel syndrome
- the invention also relates to a method for treatment of disorders using one or more compounds according to claim 1, a pharmaceutical composition according to claim 3 or a combination according to claim 4, wherein the disorders are pain, coughing, asthma, cancer, anxiety, cardiac hypertrophy, diabetes, obesity, metabolic disorders, irritable bowel syndrome (IBS), Ulcus colitis, Crohn's disease.
- disorders are pain, coughing, asthma, cancer, anxiety, cardiac hypertrophy, diabetes, obesity, metabolic disorders, irritable bowel syndrome (IBS), Ulcus colitis, Crohn's disease.
- IBS irritable bowel syndrome
- the synthetic capsaicin analogs can be used in combinations with other agonist as for instance given in the review by Kaneko, Y. et al British Journal of Pharmacology (2014) 171 p 2474-2507.
- compositions for medical use as drugs can be prepared with excipients and adjuvants according to standard textbooks.
- the compounds or combinations according to the invention can be administered in all normal ways except rectally, for instance by oral, dermal, injection or inhalation administration.
- TRPV1 Transient receptor potential vanilloid 1
- TRPV1 Transient receptor potential vanilloid 1
- TRPV1 cells were grown in a 384 well plate and loaded with Calcium 5, a fluorescent probe that reports changes in intracellular calcium.
- TRPV1 channel activity was assayed by measuring a baseline signal followed by application of TRPVl channel activator (agonist). Influx of calcium through TRPVl channels was detected as a rise in cytoplasmic calcium, which was reported as an increase in fluorescence.
- HEK293 cells stably expressing the human TRPVl channel which under control of the T- REx promoter and induced with tetracycline and HEK293 parental cells were cultured in a humidified and air-controlled (5% C0 2 ) incubator at 37 °C.
- Culture media were as following:
- pH is adjusted with 1M NaOH to pH7.4
- Phenylcapsaicin were weighed and dissolved in DMSO as shown in below table:
- Phenylcapsaicin (30mM stock) was diluted further into 6mM stock.
- Induce channel expression add tetracycline to the TRPV1 cell suspension to a final concentration of lug/ml in order to induce expression of the channel.
- the compound was diluted into DMSO and made stock solution of 6 mM.
- the stock solution were further diluted in DMSO in 3 fold series to make sub-stock solutions.
- the stock and sub-stock solutions were diluted into assay buffer to achieve 3 x final concentration for testing in compound plate. There were total 11 concentrations tested. The top test concentrations on cells were 10 uM, the final DMSO concentration on cells was 0.13%. Meanwhile, 0.13% DMSO was used as negative control.
- Test compound addition after sample 10 15 ⁇ 1 compounds were added to 30 ⁇ 1 cell plate giving 1:3 dilution
- Post test-compound read samples l l-180 (ls a read for samples 11-60, 2s a read for samples 61-180)
- Phenylcapsaicin had potent agonist effect on TRPV1 cells. 4. The EC50 of Phenylcapsaicin on TRPV1 was 57.81 nM.
- Phenylcapsaicin had no effect on HEK293 cells.
- Capsaicin and Phenylcapsaicin are rapidly absorbed from the gastro-intestinal tract and almost completely metabolized.
- the major route of excretion was biliary excretion and therefore, in the mass balance study, the majority of metabolites were detected in feces. Although the low recovery lowers the reliability of the study, derivation of reference values is still possible when considering a correction factor for systemic exposure.
- the metabolic pathways identified for Capsaicin and Phenylcapsaicin are identical, although the major metabolite is glucuronidated and oxidated for Phenylcapsaicin while the major metabolite of capsaicin is just glucuronidated. Tissue accumulation is unlikely to occur for both substances. In conclusion, the data support the read-across from capsaicin to close data gaps of phenylcapsaicin.
- the 14C located on the carbonyl group could easily be lost from the fatty acid chain and transferred to 14C-acetyl coenzyme A upon hydrolysis of the amide linkage, which means the radioactivity generated from 14C could be transferred to numerous endogenous substances.
- the author of the study concluded that therefore un-assigned radioactive peaks on the radiochromatograms are most likely endogenous substances which acquired their radioactivity from the biochemical metabolism of 14Clabeled fatty acid chain.
- Such metabolism of 14C-labeled fatty acid chain could also explain the low recovery in the mass balance studies, as the biochemical product of fatty acid chain could either be numerous 14C -endogenous substances which are finally exhaled as 14C02.
- Acute Oral Tox - QECD 423 2000 mg/Kg is applied by oral without produce mortality. Based on the test results, the test substance is unclassified according to the GHS.
- test item 0,5 mL was applied to the a gauze patch, then cover the gauze patch on a small area (approximately 6 cm 2 ) of skin, which is held in place with non-irritating tape.
- the test item is non-irritationg to the rabbits skin within an observation period of up to 14 days starting after an exposure time of 4 hours.
- test item 0,1 ml of the test item was placed in the conjunctival sac of one eye of rabbit.
- the test substance is slightly irritant to the rabbit eye within an observation period of up to 7 days without washout after the test substance was placed in the conjunctival sac of one eye.
- phenylcapsaicin is not greater than 5.65 mg/L in male and female rats based on active substance.
- test item All animals survived throughout the test period without showing any clinical signs of toxicity. Under the conditions of the present study it can be stated that the test item
- Phenylcapsaicin caused no reactions identified as sensitisation at the tested concentration. According to Commission Regulation (EU) No. 286/2011 as well as GHS (Globally Harmonized Classification System) the test item Phenylcapsaicin has no obligatory labelling requirement for skin sensitisation and is unclassified.
- EU Commission Regulation
- GHS Globally Harmonized Classification System
- Phenylcapsaicin did not cause gene mutations by base pair changes or frameshifts in the genome of the tester strains used. Therefore, Phenylcapsaicin is considered to be non-muytagenic in this bacterial reverse mutation assay.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to synthetic capasaicin analogs as TRPV1 agonists and uses thereof for prophylactic and therapeutic use.
Description
Title of Invention
Synthetic capasaicin analogs as TRPVl agonists. Field of the invention and related prior art
The transient receptor potential cation channel subfamily V member 1 (TrpVl), also known as the capsaicin receptor and the vanilloid receptor 1, is a protein that, in humans, is encoded by the TRPVl gene. It was the first isolated member of the transient receptor potential vanilloid receptor proteins that in turn are a sub-family of the transient receptor potential protein group. This protein is a member of the TRPV group of transient receptor potential family of ion channels.
The function of TRPVl is detection and regulation of body temperature. In addition, TRPVl provides a sensation of scalding heat and pain (nociception).
TRPVl is a nonselective cation channel that may be activated by a wide variety of exogenous and endogenous physical and chemical stimuli. The best-known activators of TRPVl are: temperature greater than 43 °C (109 °F); acidic conditions; capsaicin, the irritating compound in hot chili peppers; and allyl isothiocyanate, the pungent compound in mustard and wasabi. The activation of TRPVl leads to a painful, burning sensation. Its endogenous activators include: low pH (acidic conditions), the endocannabinoid anandamide, N-oleyl-dopamine, and N-arachidonoyl-dopamine. TRPVl receptors are found mainly in the nociceptive neurons of the peripheral nervous system, but they have also been described in many other tissues, including the central nervous system. TRPVl is involved in the transmission and modulation of pain (nociception), as well as the integration of diverse painful stimuli.
A review of TRPVl agonists are given by Kaneko, Y. et al British Journal of
Pharmacology (2014) 171 p 2474-2507.
The problem with many TRPVl agonists is their toxicity, and side effects. Different antagonist also have different selectivity and therapeutic effects.
Naturally occurring and isolated capsaicin have been shown to be a potent TRPVl agonist. However the substance is toxic. The available amounts of naturally occurring capsaicin is limited and expensive. Natural capsaicin extracts contains at least 3 isomers, which all
have different chemical properties. The amounts of these isomers and type and amount of additional isolated compounds will also depend on the natural source and the isolation procedure. It is thus difficult to obtain capsaicin extracts with sufficiently uniform purity and composition for an intended use. Naturally occuring capsacin has proved difficult to synthezise in high quality and yields. aXichem is a global supplier of natural-analogue industrial compounds and their mission is to develop, patent and market natural- analogue substances. aXichem has been focusing on synthetic analogues of natural capsaicin. Phenylcapsaicin is not environmentally harmful and is thus a viable alternative to natural capsaicin within a wide range of uses. aXichem holds European (EP1670310) and US patents (US7446226) on synthetic capsaicin analogs, their synthesis and use as antifouling agent (WO2005025314). These synthetic low toxicity analogs of capsaicin can by synthezised with high purity with a reasonable cost and in high yield. Phenylcapsaicin has proved to be less toxic and far less irritating than natural capsaicin.
Summary of the invention
The invention relates to at least one chemical compound with the general formula (1)
i
wherein R is a substituent selected from the group of Ci-Cis alkyl, trifluoromethyl, C3-C12 cycloalkyl, phenyl, phenoxy, phenylthio, halogen; or tautomers or salts thereof, for use as TRPV1 agonist(s).
The inventions also relates to pharmaceutical compositions, formulations and compositions comprising compounds of formula (1) according to claim 1.
The invention also relates to compounds, formulations and pharmaceutical compositions for treatment of diseases as defined in the claims 7 and 8.
Detailed description of the invention
The invention relates to at least one chemical compound with the general formula (1)
1
wherein R is a substituent selected from the group of Ci-Cis alkyl, trifluoromethyl, C3-C12 cycloalkyl, phenyl, phenoxy, phenylthio, halogen; or tautomers or salts thereof, for use as TRPVl agonist(s).
A preferred compound according to claim 1, is phenylcapsaicin.
The invention also relates to a pharmaceutical composition comprising a compound according to any of the claims 1 or 2 and optional carriers and adjuvants, for use as TRPVl agonist(s).
Further, the invention relates to a combination comprising a compound according to any of the claims 1 or 2 or a composition according to claim 3 with one or more additional antagonist(s) selected form the group consisting of resiniferatoxin, piperine, curcumin, capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide.
The invention also relates to a pharmaceutical composition according to claim 3 or a combination according to claim 4, wherein the concentration of a compound of formula (1) according to claim 1 is between 2 and 500 ppm, preferably between 2 and 50 ppm even more preferably between 2 and 20 ppm.
The invention also relates to a compound according to claim 1, a pharmaceutical composition according to claim 3 or a combination according to claim 5, for use as TRPVl agonists in animals, preferably humans.
A compound according to claim 1 a pharmaceutical composition according to claim 3 or a combination according to claim 4 for treatment or prophylactic use for pain, coughing,
asthma, cancer, anxiety, cardiac hypertrophy, diabetes, obesity, metabolic disorders, irritable bowel syndrome (IBS), Ulcus colitis, Crohn's disease.
The invention also relates to a method for treatment of disorders using one or more compounds according to claim 1, a pharmaceutical composition according to claim 3 or a combination according to claim 4, wherein the disorders are pain, coughing, asthma, cancer, anxiety, cardiac hypertrophy, diabetes, obesity, metabolic disorders, irritable bowel syndrome (IBS), Ulcus colitis, Crohn's disease.
Formulations, compositions and administration
The synthetic capsaicin analogs can be used in combinations with other agonist as for instance given in the review by Kaneko, Y. et al British Journal of Pharmacology (2014) 171 p 2474-2507.
Pharmaceutical compositions for medical use as drugs can be prepared with excipients and adjuvants according to standard textbooks.
The compounds or combinations according to the invention can be administered in all normal ways except rectally, for instance by oral, dermal, injection or inhalation administration.
Figures
Figure 1. Dose response curves of phenylcapsaicin on TRPV1 and HEK 293.
Experimental/Results
Synthetic capsaicin as TPRV1 agonists
Effects of Phenylcapsaicin on TRPV1 Stably Expressed HEK293 cells using FLIPR:
The objective of this study was to test the effects Phenylcapsaicin on HEK293 cell line and TRPV1 (Transient receptor potential vanilloid 1) stably expressed cell line using FLIPR. In brief, TRPV1 cells were grown in a 384 well plate and loaded with Calcium 5, a fluorescent probe that reports changes in intracellular calcium. TRPV1 channel activity
was assayed by measuring a baseline signal followed by application of TRPVl channel activator (agonist). Influx of calcium through TRPVl channels was detected as a rise in cytoplasmic calcium, which was reported as an increase in fluorescence.
HEK293 cells stably expressing the human TRPVl channel which under control of the T- REx promoter and induced with tetracycline and HEK293 parental cells were cultured in a humidified and air-controlled (5% C02) incubator at 37 °C. Culture media were as following:
pH is adjusted with 1M NaOH to pH7.4
Phenylcapsaicin were weighed and dissolved in DMSO as shown in below table:
Phenylcapsaicin (30mM stock) was diluted further into 6mM stock.
Cell preparation was initiated 1 day before the FLIPR experiment.
1. Passage cells when they were at approximately 80- 90% confluence.
2. Re-suspend pellet in lOmls of warm media, count cells and adjust to the appropriate
concentration (5xl05/ml for TRPV1 and 4xl05/ml for HEK293) using warm media .
3. Induce channel expression: add tetracycline to the TRPV1 cell suspension to a final concentration of lug/ml in order to induce expression of the channel.
4. Plate out cells at 50ul/well in 384 well cell plates as shown below and incubate overnight in a humidified and air-controlled (5% C02) incubator at 37 °C.
Loading dye:
1. On the day of the assay, prepare loading buffer using Assay buffer according to the kit manual.
2. Remove media from cells by inversion the cell plate and centrifuge.
3. Add 30ul of loading dye per well to the cell plate.
4. Allow the cells to be incubated with dye for 1 hour in the dark at room temperature. Compound plate preparation:
The compound was diluted into DMSO and made stock solution of 6 mM. The stock solution were further diluted in DMSO in 3 fold series to make sub-stock solutions.
Immediately prior to running the assay, the stock and sub-stock solutions were diluted into assay buffer to achieve 3 x final concentration for testing in compound plate. There were total 11 concentrations tested. The top test concentrations on cells were 10 uM, the final DMSO concentration on cells was 0.13%. Meanwhile, 0.13% DMSO was used as negative control.
FLIPR reading:
1. After 1 hour loading, cell plate and compound plate were mounted to FLIPR for reading. Protocol details were as below:
Excitation wavelength (nm): 470-495 Emission Wavelength (nm): 515-575
Baseline read: samples 1-10 (Is a read)
Test compound addition after sample 10: 15μ1 compounds were added to 30μ1 cell plate giving 1:3 dilution
Post test-compound read: samples l l-180 (ls a read for samples 11-60, 2s a read for samples 61-180)
2. Data was automatically captured at the end of FLIPR experiment. The peak value of fluorescence signal (the maximum value) was used for data export after ' Subtract bias based on sample for further data analysis.
Data were analyzed using Excel 2007 and GraphPad Prism.
Results
The data of top concentration and DMSO control was used for z factor and S/N
calculation.
Dose response curves
Conclusions
1. Three data points were excluded and not used for data analysis which didn't affect the results.
2. Good z factors were achieved for Phenylcapsaicin on TRPV1 cells.
3. Phenylcapsaicin had potent agonist effect on TRPV1 cells.
4. The EC50 of Phenylcapsaicin on TRPV1 was 57.81 nM.
5. Phenylcapsaicin had no effect on HEK293 cells.
Toxicity studies
Comparative toxicity data between capsaicin and phenylcapsaicin:
Capsaicin and Phenylcapsaicin are rapidly absorbed from the gastro-intestinal tract and almost completely metabolized. The major route of excretion was biliary excretion and therefore, in the mass balance study, the majority of metabolites were detected in feces. Although the low recovery lowers the reliability of the study, derivation of reference values is still possible when considering a correction factor for systemic exposure. The metabolic pathways identified for Capsaicin and Phenylcapsaicin are identical, although the major metabolite is glucuronidated and oxidated for Phenylcapsaicin while the major metabolite of capsaicin is just glucuronidated. Tissue accumulation is unlikely to occur for both substances. In conclusion, the data support the read-across from capsaicin to close data gaps of phenylcapsaicin.
The 14C located on the carbonyl group could easily be lost from the fatty acid chain and transferred to 14C-acetyl coenzyme A upon hydrolysis of the amide linkage, which means the radioactivity generated from 14C could be transferred to numerous endogenous substances. The author of the study concluded that therefore un-assigned radioactive peaks on the radiochromatograms are most likely endogenous substances which acquired their
radioactivity from the biochemical metabolism of 14Clabeled fatty acid chain. Such metabolism of 14C-labeled fatty acid chain could also explain the low recovery in the mass balance studies, as the biochemical product of fatty acid chain could either be numerous 14C -endogenous substances which are finally exhaled as 14C02. Low radioactivity in carcasses at the end of the study support thatl4C -phenyl-capsaicin and 14C-capsaicin was biotransformed to other 14C-labeled volatile organic compounds in multiple steps and these metabolites were gradually released as expired air via the lung. If needed correction of the internal reference values (AEL) using the total recovery (50%) seems to be valid as the majority of metabolites are excreted in bile. Only 2-3% parent were detected in bile. Thus systemic availablity of the a.s. is likely. A complete absorption of Capsaicin was also postulated by
Donnerer et al. 1990. Naunyn-Schmiedeberg's Arch. Pharmacol., 342, 357-361)
Acute Oral Tox - QECD 423:
2000 mg/Kg is applied by oral without produce mortality. Based on the test results, the test substance is unclassified according to the GHS. The acute oral toxicity LD50 value: LD50 > 5000 mg/Kg.
Acute Dermal Irritation/Corrosion - QECD 404:
The test item 0,5 mL was applied to the a gauze patch, then cover the gauze patch on a small area (approximately 6 cm2) of skin, which is held in place with non-irritating tape. The test item is non-irritationg to the rabbits skin within an observation period of up to 14 days starting after an exposure time of 4 hours.
Acute Eye Irritation/Corrosion - QECD 405:
0,1 ml of the test item was placed in the conjunctival sac of one eye of rabbit. The test substance is slightly irritant to the rabbit eye within an observation period of up to 7 days without washout after the test substance was placed in the conjunctival sac of one eye.
Acute Inhalation Tox - QECD 403, 2009:
Under the condtions of this study the single exposure acute inhalation LC50 of
phenylcapsaicin is not greater than 5.65 mg/L in male and female rats based on active substance.
Skin Sensitisation - QECD 406, 1992:
All animals survived throughout the test period without showing any clinical signs of toxicity. Under the conditions of the present study it can be stated that the test item
Phenylcapsaicin caused no reactions identified as sensitisation at the tested concentration. According to Commission Regulation (EU) No. 286/2011 as well as GHS (Globally Harmonized Classification System) the test item Phenylcapsaicin has no obligatory labelling requirement for skin sensitisation and is unclassified.
Reverse Mutation Assay - QECD 471, 1997:
In conclusion, it can be stated that during the described mutagenicity test and under the experimental conditions reported, Phenylcapsaicin did not cause gene mutations by base pair changes or frameshifts in the genome of the tester strains used. Therefore,
Phenylcapsaicin is considered to be non-muytagenic in this bacterial reverse mutation assay.
Claims
1. At least one chemical compound with the general formula (1)
wherein R is a substituent selected from the group of Ci-Cis alkyl, trifluoromethyl, C3- Ci2 cycloalkyl, phenyl, phenoxy, phenylthio, halogen; or tautomers or salts thereof, for use as TRPV1 agonist(s).
2. A compound according to claim 1, which is phenylcapsaicin.
3. A pharmaceutical composition comprising a compound according to any of the claims 1 or 2 and optional carriers and adjuvants, for use as TRPV1 agonist(s).
4. A combination comprising a compound according to any of the claims 1 or 2 or a composition according to claim 3 with one or more additional antagonist(s) selected form the group consisting of resiniferatoxin, piperine, curcumin, capsaicin,
dihydrocapsaicin, nordihydrocapsaicin, homodihy drocap s aicin , homocapsaicin, nonivamide.
5. A pharmaceutical composition according to claim 3 or a combination according to claim 4, wherein the concentration of a compound of formula (1) according to claim 1 is between 2 and 500 ppm, preferably between 2 and 50 ppm even more preferably between 2 and 20 ppm.
6. A compound according to claim 1, a pharmaceutical composition according to claim 3 or a combination according to claim 5, for use as TRPV1 agonists in animals, preferably humans.
7. A compound according to claim 1 a pharmaceutical composition according to claim 3 or a combination according to claim 4 for treatment or prophylactic use for pain, coughing, asthma, cancer, anxiety, cardiac hypertrophy, diabetes, obesity, metabolic disorders, irritable bowel syndrome (IBS), Ulcus colitis, Crohn's disease.
8. Method for treatment of disorders using one or more compounds according to claim 1, a pharmaceutical composition according to claim 3 or a combination according to claim 4, wherein the disorders are pain, coughing, asthma, cancer, anxiety, cardiac hypertrophy, diabetes, obesity, metabolic disorders, irritable bowel syndrome (IBS), Ulcus colitis, Crohn's disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20160467 | 2016-03-18 | ||
| NO20160467 | 2016-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017160156A1 true WO2017160156A1 (en) | 2017-09-21 |
Family
ID=59851329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/NO2017/050062 WO2017160156A1 (en) | 2016-03-18 | 2017-03-09 | Synthetic capasaicin analogs as trpv1 agonists |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2017160156A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3443956A1 (en) * | 2017-08-18 | 2019-02-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A compound increasing endocannabinoids concentration in a subject for use for preventing and/or treating a social behavior disorder |
| WO2019077115A1 (en) * | 2017-10-20 | 2019-04-25 | Axichem Ab | Synthetic capsaicin analogues as bioenhancers |
| NO20201253A1 (en) * | 2020-11-17 | 2022-05-18 | Axichem Ab | Capsaicyns in the treatment of leaky gut |
| NO346587B1 (en) * | 2021-06-02 | 2022-10-17 | Axichem Ab | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis |
| NO20220225A1 (en) * | 2022-02-18 | 2023-08-21 | Axichem Ab | Bioenhancers |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102060689A (en) * | 2010-12-14 | 2011-05-18 | 台州市华南医化有限公司 | Synthetic method of phenyl capsaicin midbody 7-phenyl-6-heptynoic acid |
| US20120027693A1 (en) * | 2010-07-27 | 2012-02-02 | Bean Bruce P | Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise |
| US20130197094A1 (en) * | 2012-02-01 | 2013-08-01 | Warsaw Orthopedic, Inc. | Trpv1 compounds in a biodegradable polymer carrier |
| WO2015160843A1 (en) * | 2014-04-14 | 2015-10-22 | Flex Pharma, Inc. | Ion channel activators and methods of use |
| WO2015160842A1 (en) * | 2014-04-14 | 2015-10-22 | Flex Pharma, Inc. | Methods and formulatiions of capsaicinoids and capsinoids |
-
2017
- 2017-03-09 WO PCT/NO2017/050062 patent/WO2017160156A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120027693A1 (en) * | 2010-07-27 | 2012-02-02 | Bean Bruce P | Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise |
| CN102060689A (en) * | 2010-12-14 | 2011-05-18 | 台州市华南医化有限公司 | Synthetic method of phenyl capsaicin midbody 7-phenyl-6-heptynoic acid |
| US20130197094A1 (en) * | 2012-02-01 | 2013-08-01 | Warsaw Orthopedic, Inc. | Trpv1 compounds in a biodegradable polymer carrier |
| WO2015160843A1 (en) * | 2014-04-14 | 2015-10-22 | Flex Pharma, Inc. | Ion channel activators and methods of use |
| WO2015160842A1 (en) * | 2014-04-14 | 2015-10-22 | Flex Pharma, Inc. | Methods and formulatiions of capsaicinoids and capsinoids |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3443956A1 (en) * | 2017-08-18 | 2019-02-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A compound increasing endocannabinoids concentration in a subject for use for preventing and/or treating a social behavior disorder |
| WO2019077115A1 (en) * | 2017-10-20 | 2019-04-25 | Axichem Ab | Synthetic capsaicin analogues as bioenhancers |
| CN111479565A (en) * | 2017-10-20 | 2020-07-31 | 艾克西化学公司 | Synthetic capsaicin analogs as bioenhancers |
| JP2021500402A (en) * | 2017-10-20 | 2021-01-07 | アクシシェム アクティエボラーグ | Synthetic capsaicin analog as a bioenhancer |
| US11471429B2 (en) | 2017-10-20 | 2022-10-18 | Axichem Ab | Synthetic capsaicin analogues as bioenhancers |
| AU2018351640B2 (en) * | 2017-10-20 | 2024-02-29 | Axichem Ab | Synthetic capsaicin analogues as bioenhancers |
| NO20201253A1 (en) * | 2020-11-17 | 2022-05-18 | Axichem Ab | Capsaicyns in the treatment of leaky gut |
| WO2022106394A1 (en) * | 2020-11-17 | 2022-05-27 | Axichem Ab | Capsaicyns in the treatment of leaky gut |
| NO346665B1 (en) * | 2020-11-17 | 2022-11-21 | Axichem Ab | Capsaicyns in the treatment of leaky gut |
| NO346587B1 (en) * | 2021-06-02 | 2022-10-17 | Axichem Ab | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis |
| NO20220225A1 (en) * | 2022-02-18 | 2023-08-21 | Axichem Ab | Bioenhancers |
| WO2023156589A1 (en) * | 2022-02-18 | 2023-08-24 | Axichem Ab | Capsaicin derivatives as bioenhancers on active substances metabolized by cyp1a2 and cyp2d6 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017160156A1 (en) | Synthetic capasaicin analogs as trpv1 agonists | |
| JP6175172B2 (en) | Methods for inhibiting muscle atrophy | |
| Solt et al. | Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand | |
| AU2013291925B2 (en) | Test kit for the quantitative determination of narcotic drugs | |
| US20100304998A1 (en) | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins | |
| WO2021195507A1 (en) | Methods and compositions for treating viral infections | |
| CN103037692A (en) | Methods for inhibiting muscle atrophy | |
| CN115103670A (en) | Transcription Enhancement Associated Domain (TEAD) transcription factor inhibitors and uses thereof | |
| WO2012054718A2 (en) | Treating long qt syndrome | |
| US20200115320A1 (en) | Therapeutic compounds and methods of use | |
| Mazzanti et al. | New β-adrenergic agonists used illicitly as growth promoters in animal breeding: chemical and pharmacodynamic studies | |
| Beattie et al. | A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of β2-adrenoceptor agonists as inhaled long-acting bronchodilators | |
| Grand et al. | Discovery of icenticaftor (QBW251), a cystic fibrosis transmembrane conductance regulator potentiator with clinical efficacy in cystic fibrosis and chronic obstructive pulmonary disease | |
| de Jong et al. | The risk of emerging new psychoactive substances: the first fatal 3-MeO-PCP intoxication in The Netherlands | |
| Kaushal et al. | Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo | |
| Srejovic et al. | The effects of the modulation of NMDA receptors by homocysteine thiolactone and dizocilpine on cardiodynamics and oxidative stress in isolated rat heart | |
| DE112007003375T5 (en) | Imidazole derivatives that induce apoptosis and their therapeutic use | |
| US20200003759A1 (en) | Methods for identifying metap-2 modulators | |
| US10487045B2 (en) | Adamantane derivative and use thereof | |
| Bryk et al. | Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor EB | |
| US20130324598A1 (en) | Treating mycobacterial infection with cu+/++ boosting therapeutics | |
| JP2021191804A (en) | Method of treatment and compositions comprising dual pi3k delta-gamma kinase inhibitor and corticosteroid | |
| EP3207926B1 (en) | Oxidized lipids in the treatment of chronic or neuropathic pain | |
| Sadler et al. | Transient receptor potential canonical 5 (TRPC5) mediates inflammatory mechanical pain | |
| Gao et al. | Synthesis and Pharmacological Characterization of a Difluorinated Analogue of Reduced Haloperidol as a Sigma-1 Receptor Ligand |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17767039 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 23.11.2018) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17767039 Country of ref document: EP Kind code of ref document: A1 |